

SUPPLEMENTARY FIGURES



Supplementary Figure 1. Usenamine A inhibits the proliferation, migration, and invasion of LUAD cells (A549). (A) Cell proliferation was detected using a colony formation assay. (B) Cell migration was measured using a wound-healing assay. Scale bar = 50 μ m. (C) Cell migration and invasion were determined using the transwell assay. Scale bar = 50 μ m. (D) Cell apoptosis was assessed using flow cytometry. ** $p < 0.01 vs. 0 \mu$ g/mL usenamine A; #p < 0.05 and ## $p < 0.01 vs. 1 \mu$ g/mL usenamine A; \$p < 0.05 and \$\$ $p < 0.01 vs. 2 \mu$ g/mL usenamine A.



Supplementary Figure 2. Usenamine A induces NLRP3/caspase-1/GSDMD-mediated pyroptosis in LUAD cells (A549). (A) Levels of ROS in the cells were detected using a DCFH-DA probe. Scale bar = 25 μ m. (B) LDH, IL-1 β , and IL-18 levels in the cells were measured using commercial ELISA kits. (C) Representative morphological images of cells obtained by microscopic examination. Scale bar = 50 μ m. (D) Relative expression of caspase-1, -4, -5, and -8 was analyzed using RT-qPCR. (E) Relative protein expression of NLRP3/caspase-1/GSDMD pathway-related proteins was measured using western blotting. *p < 0.05 and **p < 0.01 vs. 0 μ g/mL usenamine A; p < 0.05 and p < 0.01 vs. 2 μ g/mL usenamine A. GSDMD, gasdermin D; LUAD, lung adenocarcinoma; NLRP3, NOD-like receptor pyrin 3; RT-qPCR, reverse transcription-quantitative PCR.